Navigation Links
New Research Uncovers Elusive Target of Antifungal Agent
Date:6/13/2010

A research team in Japan has uncovered the mechanism underlying the antifungal activity of theonellamide (TNM), a bioactive compound found in a species of marine sponge. The finding, reported in Nature Chemical Biology, provides new insights toward the development of antifungal drugs, with broader applications to drug analysis in areas such as cancer research.

(PRWeb UK) June 13, 2010 -- A research team in Japan has uncovered the mechanism underlying the antifungal activity of theonellamide (TNM), a bioactive compound found in a species of marine sponge. The finding, reported in Nature Chemical Biology, provides new insights toward the development of antifungal drugs, with broader applications to drug analysis in areas such as cancer research.

Designing drugs that target fungal cells poses serious challenges due to their similarity to human cells at the molecular level. To avoid damaging human cells, such drugs exploit differences between mammalian and fungal cells, both of which, unlike bacteria, are in the same family of eukaryotes. The difficulty of this task results in toxic side effects and a shortage of effective antifungal agents.

The research team, headed by scientists at the RIKEN Advanced Science Institute, set out to tackle this problem by investigating the antifungal activity of theonellamides (TNMs), bicyclic peptides found in the marine sponge Theonella, on the fission yeast. Combining chemical-genetic profiling and biochemical and cellular analysis, they deduced that TNMs bind to a class of lipid molecules (3?-hydroxysterols) in the cell membrane to induce overproduction of 1,3-?-D-glucan, a component of the cell wall.

Antifungal activity in TNMs, the researchers showed, is thus different from other antifungals, which cause damage by impairing wall synthesis. Instead, TNMs damage fungal cells by abnormally promoting such synthesis, targeting not proteins as previously thought, but a class of lipids, including ergosterol. TNMs thus represent an entirely new class of sterol-binding molecules, offering a new direction in the development of antifungal agents and a powerful tool for drug analysis.

For more information, please contact:

Dr. Minoru Yoshida
Chemical Genomics Research Group
RIKEN Advanced Science Institute
Tel: +81-(0)48-467-9516 / Fax: +81-(0)48-467-4676

Ms. Tomoko Ikawa (PI officer)
Global Relations Office
RIKEN
Tel: +81-(0)48-462-1225 / Fax: +81-(0)48-462-4715

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4131144.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Research Uncovers Elusive Target of Antifungal Agent
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... HealthCareMandA.com ... —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , Home health and hospice companies are still popular targets ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee replacement ... (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- According to a new market research report "Medical Radiation ... Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), Safety (Apron, Shields, Face ... market is expected to reach USD 1,215.4 Million by 2021 from USD ... 2021. Continue Reading ... ...
(Date:3/29/2017)... 29, 2017  The Pharmaceutical Care Management Association (PCMA) ... report on patient out-of-pocket spending: ... Services (CMS), the average amount spent out-of-pocket for drugs ... spending in 2016, down from 23% in 2006. ... not a coverage problem. Health plans don,t have unlimited ...
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
Breaking Medicine Technology: